|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament light distinguished neurodegenerative or neurological disorder from psychiatric disorder with an area under the curve of 0.94 (95% confidence intervals = [0.89, 0.98]); a cut-off of 1332 pg/mL was associated with 87% sensitivity and 90% specificity.
|
31220922 |
2020 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament light chain (NfL) is a unique biomarker related to axonal damage and neural cell death, which is elevated in a number of neurological disorders, and can be detected in cerebrospinal fluid (CSF), as well as blood, serum, or plasma samples.
|
31385229 |
2020 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament light chain as a biomarker in neurological disorders.
|
30967444 |
2019 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated levels of the cerebrospinal fluid (CSF) neuronal injury markers (neurofilament light chain [NF-L] and total tau protein [t-tau]) and of the astroglial marker glial fibrillary acidic protein (GFAP) are found in etiologically different neurological disorders affecting the peripheral and the central nervous system.
|
31087810 |
2019 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
We examined whether NF-L is elevated differentially following uncomplicated mTBI in older adults with pre-injury neurological disorders.
|
30843469 |
2019 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased CSF Neurofilament light chain (NFL) concentrations have been reported in several neurological disorders, including prion diseases.
|
30309804 |
2019 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
The cerebrospinal fluid (CSF) neurodegeneration biomarkers such as neurofilament light chain (NF-L), total tau (t-tau), and the tau pathology marker phosphorylated tau (p-tau) are related to mortality in other neurological disorders (eg, amyotrophic lateral sclerosis, Alzheimer's disease), but have not been investigated in this respect in parkinsonian disorders.
|
31070772 |
2019 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we review what is known about the structure and function of neurofilaments, discuss analytical aspects and knowledge of age-dependent normal ranges of neurofilaments and provide a comprehensive overview of studies on neurofilament light chain as a marker of axonal injury in different neurological disorders, including multiple sclerosis, neurodegenerative dementia, stroke, traumatic brain injury, amyotrophic lateral sclerosis and Parkinson disease.
|
30171200 |
2018 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
To confirm the large body of evidence for NfL, we developed a new ELISA method and here we present the performance characteristics of this new ELISA for CSF NfL in different neurological disorders.
|
29370869 |
2018 |
|
nervous system disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results reveal that as well as acting as reliable biomarkers of neuronal damage, antibodies to NF-L exacerbate neurological disease, suggesting that antibodies to NF-L generated during disease may also be pathogenic and play a role in the progression of neurodegeneration.
|
28718500 |
2017 |
|
nervous system disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We conducted a study including 60 sporadic and 19 familial ALS patients, 206 reference patients with other neurological disorders and 40 age- and sex-matched healthy controls to test the hypothesis that cerebrospinal fluid (CSF) levels of neurofilament light (NF-L) protein, a marker of axonal degeneration, might provide diagnostic and prognostic information on the disease.
|
17903209 |
2007 |